The Ras-mitogen activated protein kinase and phosphatidylinositol-3-kinase (PI3K)-AKT-mammalian target of rapamycin (mTOR) pathways are known to be activated in HCC and MET is known to be overexpressed in HCC [30]. The gene discussed is MET; the disease is hepatocellular carcinoma.